IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders spotthedot2022-06-29T11:39:18+00:00June 29th, 2022| Read More
IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference spotthedot2022-06-02T20:11:13+00:00June 1st, 2022| Read More
IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology spotthedot2022-03-17T02:18:53+00:00December 17th, 2021| Read More
CEO Damon Burrows featured on OIS Podcast spotthedot2022-03-17T02:23:49+00:00November 16th, 2021| Read More
IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury spotthedot2022-03-17T02:19:31+00:00October 28th, 2021| Read More
IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer spotthedot2022-03-17T02:19:53+00:00July 27th, 2021| Read More
IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain spotthedot2022-03-17T02:20:27+00:00January 7th, 2021| Read More
IACTA Pharmaceuticals featured in Orange County Business Journal’s Startups and Innovations section spotthedot2022-03-17T02:20:38+00:00August 10th, 2020| Read More
IACTA Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments spotthedot2022-03-17T02:20:49+00:00July 30th, 2020| Read More
New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia spotthedot2022-03-17T02:21:34+00:00July 28th, 2020| Read More
Connect with us